Volume 27, Issue 1 (March 2023)                   Physiol Pharmacol 2023, 27(1): 9-15 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Adelipour M, Sorkheh H, Kiani Z, Bahrami H, Berageah N, Salimi A, et al . Umbilical cord as a source of mesenchymal stem cells improves melasma in parturients: a clinicalrandomized trial. Physiol Pharmacol 2023; 27 (1) :9-15
URL: http://ppj.phypha.ir/article-1-1816-en.html
Abstract:   (940 Views)
Introduction: Melasma is a common skin problem in pregnant women that appears to be related to physiological changes. Mesenchymal stem cells (MSCs) have been used to treat skin disorders because of their direct cell-to-cell contact or release of several biomolecules. The umbilical cord, which is available at birth, is a rich source of MSCs. This study was undertaken to evaluate the effect of the umbilical cord as a natural face mask for treating women’s melasma after parturition.
Methods: This randomized clinical trial was carried out on parturients suffering from melasma. Fifty pregnant women were randomly categorized into two groups of control and treated with the umbilical cord. A section of the umbilical cord (10-20 cm) was cut immediately after parturition and used as a face mask on the face of each mother in the hyperpigmentation areas for one hour. Melasma Area Severity Index (MASI) was used to measure hyperpigmentation and calculated for each participant before and four weeks after intervention.
Results: A significant decrease in MASI was observed in the women treated with the umbilical cord (p<0.05).
Conclusion: Our findings suggested that a fresh umbilical cord, as a natural face mask containing MSCs, can improve the melasma in the parturients.
Full-Text [PDF 1640 kb]   (361 Downloads)    

1. Bajetto A, Pattarozzi A, Corsaro A, Barbieri F, Daga A, Bosio A, et al. Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front Cell Neurosci 2017; 11: 312. [DOI:10.3389/fncel.2017.00312]
2. Barankin B, Silver SG, Carruthers A. The skin in pregnancy. J Cutan Med Surg 2002; 6: 236-40. [DOI:10.1177/120347540200600308]
3. Chen H, Niu J-W, Ning H-M, Pan X, Li X-B, Li Y, et al. Treatment of psoriasis with mesenchymal stem cells. Am J Med 2016; 129: 13-14. [DOI:10.1016/j.amjmed.2015.11.001]
4. Ezquer FE, Ezquer ME, Vicencio JM, Calligaris SD. Two complementary strategies to improve cell engraftment in mesenchymal stem cell-based therapy: Increasing transplanted cell resistance and increasing tissue receptivity. Cell Adh Migr 2017; 11: 110-9. [DOI:10.1080/19336918.2016.1197480]
5. Geraghty LN, Pomeranz MK. Physiologic changes and dermatoses of pregnancy. Int J Dermatol 2011; 50: 771-82. [DOI:10.1111/j.1365-4632.2010.04869.x]
6. Grimes P, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol 2019; 5: 30-6. [DOI:10.1016/j.ijwd.2018.09.004]
7. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006; 55: 1048-65. [DOI:10.1016/j.jaad.2006.02.009]
8. Hughes EC, Saleh D. Telogen effluvium. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2017.
9. Lakhdar H, Zouhair K, Khadir K, Essari A, Richard A, Seité S, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol 2007; 21: 738-42. [DOI:10.1111/j.1468-3083.2007.02185.x]
10. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, KIM MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 2006; 32: 626-31. [DOI:10.1097/00042728-200605000-00004]
11. McKesey J, Tovar-Garza A, Pandya AG. Melasma treatment: An Evidence-Based Review. Am J Clin Dermatol 2019: 1-53. [DOI:10.1007/s40257-019-00488-w]
12. Ortonne J-P, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 2008;13(1):10-4. [DOI:10.1038/jidsymp.2008.7]
13. Shin T-H, Kim H-S, Choi SW, Kang K-S. Mesenchymal stem cell therapy for inflammatory skin diseases: Clinical potential and mode of action. Int J Mol Sci 2017; 18: 244. [DOI:10.3390/ijms18020244]
14. Shojaei F, Rahmati S, Banitalebi Dehkordi M. A review on different methods to increase the efficiency of mesenchymal stem cell-based wound therapy. Wound Repair Regen 2019; 27: 661-71. [DOI:10.1111/wrr.12749]
15. Sivakumaran N, Rathnayaka IR, Shabbir R, Wimalsinghe SS, Jayakody J, Chandrasekaran M. Umbilical cord blood banking and its therapeutic uses. Int j sci res innov technol 2018; 5: 160.
16. Teresa Conconi M, Di Liddo R, Tommasini M, Calore C, Paolo Parnigotto P. Phenotype and differentiation potential of stromal populations obtained from various zones of human umbilical cord: an overview. J Tissue Eng Regen Med 2011; 4. [DOI:10.2174/1875043501104010006]
17. Urasaki MBM. Skin physiological alterations perceived by pregnant women attended at public health services. Acta Paulista de Enfermagem 2010; 23: 519-25. [DOI:10.1590/S0103-21002010000400012]
18. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-16. [DOI:10.1016/j.exphem.2005.07.003]
19. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-7. [DOI:10.1634/stemcells.2004-0013]
20. Wu Y, Huang S, Enhe J, Ma K, Yang S, Sun T, et al. Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice. Int Wound J 2014; 11: 701-10. [DOI:10.1111/iwj.12034]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.